New Thinking on Neurodevelopment by Szpir, Michael
Environews Focushe notion that some substances in
the environment can damage the
nervous system has an ancient history.
The neurotoxicity of lead was recog-
nized more than 2,000 years ago by the
Greek physician Dioscerides, who
wrote, “Lead makes the mind give way.”
In the intervening millennia many
other substances have been added to the
list of known or suspected neurotoxi-
cants. Despite this accumulation of
knowledge, there is still much that isn’t
understood about how neurotoxicants
affect the developing brain, especially
the effects of low-dose exposures. Today
researchers are taking a hard look at
low-dose exposures in utero and during
childhood to unravel some of the mys-
teries of impaired neurodevelopment.
About 17% of school-age children
in the United States suffer from a dis-
ability that affects their behavior, mem-
ory, or ability to learn, according to a
study published in the March 1994
issue of Pediatrics by a team from
the Centers for Disease Control and
Prevention (CDC). The list of maladies
includes attention deficit/hyperactivity
disorder (ADHD), autistic spectrum
disorders, epilepsy, Tourette syndrome,
and less specific conditions such as
mental retardation and cerebral palsy.
All are believed to be the outcome of
some abnormal process that unfolded as
the brain was developing in utero or in
the young child.
These disorders have an enormous
impact on families and society.
According to the 1996 book Learning
Disabilities: Lifelong Issues, children
with these disorders have higher rates of
mental illness and suicide, and are more
likely to engage in substance abuse and
to commit crimes as adults. The overall
economic cost of neurodevelopmental
disorders in the United States is esti-
mated to be $81.5–167 billion per
year, according to a report published
in the December 2001 issue of EHP
Supplements. 
Potentially even more disturbing is
that a number of epidemiologic studies
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suggest that the incidence of certain disorders
is on the rise. In the United States, the diag-
nosis of autistic spectrum disorders increased
from 4–5 per 10,000 children in the 1980s
to 30–60 per 10,000 children in the 1990s,
according to a report in the August 2003
Journal of Autism and Developmental Dis-
orders. Similarly, notes a report in the
February 2002 issue of CNS Drugs, the diag-
nosis of ADHD grew 250% between 1990
and 1998. The number of children in special
education programs classified with learning
disabilities increased 191% between 1977
and 1994, according to an article in Advances
in Learning and Behavioral Disabilities,
Volume 12, published in 1998.
So what is going on? The short answer
is that no one really knows. There’s not
even consensus on what the soaring rates
actually mean. Heightened public aware-
ness could account for the surge in the
numbers, or it may be that physicians are
getting better at diagnosing the condi-
tions. Some autism researchers believe the
rise in that condition’s prevalence simply
reflects changes in diagnostic criteria over
the last 25 years. On the other hand, some
scientists believe that the rates of neurode-
velopmental disease are truly increasing,
and that the growing burden of chemicals
in the environment may play a role.
With that in mind, investigators are
considering the effects of gene–environ-
ment interactions. A child with a mild
genetic tendency toward a neurodevelop-
mental disorder might develop without
clinically measurable abnormalities in the
absence of environmental “hits.” However,
children in industrialized nations develop
and grow up in a veritable sea of xenobiot-
ic chemicals, says Isaac Pessah, director of
the University of California, Davis, Center
for Children’s Environmental Health and
Disease Prevention. “Fortunately,” he says,
“most of us have a host of defense mecha-
nisms that protect us from adverse out-
comes. However, genetic polymorphisms,
complex epistasis, and cytogenetic abnor-
malities could weaken these defenses and
amplify chemical damage, initiating a
freefall into a clinical syndrome.” 
Pessah cites the example of autism. He
says susceptibility for autism is likely con-
ferred by several defective genes, no one of
which can account for all the core symp-
toms of social disinterest, repetitive and
overly focused behaviors, and problems in
communication. Could multiple genetic lia-
bilities and exposure to a chemically com-
plex environment act in concert to increase
the incidence and severity of the condition? 
Despite the uncertainties, many scien-
tists believe it would be wise to err on the
side of caution when it comes to a research
agenda. As Martha Herbert, a pediatric
neurologist at Harvard Medical School,
puts it, “Even though we may have neither
consensus nor certainty about an autism
epidemic, there are enough studies coming
in with higher numbers that we should take
it seriously. Environmental hypotheses
ought to be central to research now. The
physiological systems that have been
harmed by environmental factors may also
point to treatment targets, and this might
be a great way to help the children.”
The Parade of Neurotoxicants
Among the most intensely studied neuro-
toxicants are metals (lead, mercury, and
manganese), pesticides, polychlorinated
biphenyls (PCBs), and polybrominated
diphenyl ethers (PBDEs). A number of
these compounds were identified as neuro-
toxicants when individuals were exposed to
high doses during occupational accidents or
childhood poisonings. Scientists are now
exploring the potential consequences of
low-dose exposures, especially to children
and fetuses. Epidemiologic studies play a
central role, and these are often comple-
mented by experimental work on animals
and cell cultures. These days, researchers are
looking not only at associations between
toxicants and disease, but also at the under-
lying cellular and molecular mechanisms.
Lead. Studies dating to the 1970s show
that children exposed to lead have deficits
in IQ, attention, and language. In
response, the CDC revised its limits for
acceptable blood levels of the metal in sev-
eral steps, from 60 micrograms per deciliter
(µg/dL) in the 1960s to the current level of
10 µg/dL, set in 1991. But many scientists
think that limit is still too high. A study
reported in the September 2005 issue of
EHP found that there were significant
effects on a child’s IQ even when blood
lead concentrations were below 10 µg/dL.
Upon the July 2005 release of the Third
National Report on Human Exposure to
Environmental Chemicals by the CDC, Jim
Pirkle, deputy director for science at the
CDC’s Environmental Health Laboratory,
stated, “There is no safe blood [lead] level
in children.”
Several groups have also found evidence
that lead exposure may shape a child’s social
behavior. An article in the May 2000 issue
of Environmental Research reports a strong
correlation, dating back to 1900, between
violent crime and the use of lead-based
paint and leaded gasoline. The research
complements studies by Herbert Needle-
man, a professor of psychiatry and pedi-
atrics at the University of Pittsburgh School
of Medicine, who found that bone lead lev-
els in young males were correlated with
aggression and criminality. “Lead is signifi-
cantly associated with a risk for delinquen-
cy,” says Needleman. His research appeared
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in the November–December 2002 issue
of Neurotoxicology and Teratology and the
7 February 1996 issue of JAMA.
Another new area of research links
early lead exposure to changes in the
aging brain. Nasser Zawia, an associate
professor of pharmacology and toxicology
at the University of Rhode Island,
Kingston, and his colleagues found
increased expression of amyloid precursor
protein (APP) and its product, β-amyloid
(which is a hallmark of Alzheimer dis-
ease), in aging rats that were exposed to
lead shortly after birth. In contrast, old
rats that were exposed to lead did not
show an increased expression of APP and
β-amyloid. The work, published in the 26
January 2005 issue of The Journal of
Neuroscience, suggests that early exposure
to lead can “reprogram” gene expression
and regulation later in life. According to
Zawia, preliminary research also shows
that “monkeys exposed to lead as infants
exhibit similar molecular changes as well
as exaggerated Alzheimer’s pathology.”
Mercury.  The current Environmental
Protection Agency (EPA) reference dose for
methylmercury (an organic, toxic form of
mercury) is 0.1 micrograms per kilogram
per day (µg/kg/day). Humans are exposed
to methylmercury primarily through con-
sumption of contaminated fish; a good
70% of this contamination comes from
anthropogenic sources such as emissions
from coal-fired power plants. High-level
exposure to methylmercury in the womb is
linked to a number of impairments, includ-
ing mental retardation, cerebral palsy,
seizures, deafness, blindness, and speech
difficulties. An article in the May 2005
issue of EHP puts the economic cost to the
United States of methylmercury-induced
toxicity (in terms of lost productivity) at
$8.7 billion annually.
The effects of low-dose exposures are
not so apparent. Two large epidemiologic
studies of fishing populations in the Faroe
Islands and the Seychelles have produced
conflicting results regarding low-dose
effects. Both studies sought to examine
the association between methylmercury
exposure and neurodevelopment in chil-
dren whose mothers ate contaminated
seafood during pregnancy. 
The leader of the Faroe Islands study,
Philippe Grandjean, an adjunct professor
of environmental health at the Harvard
School of Public Health, and his col-
leagues reported in the November 1997
issue of Neurotoxicology and Teratology
that 7-year-old Faroese children had sig-
nificant cognitive deficits and neurologi-
cal changes after prenatal exposure to
methylmercury. Grandjean’s team fol-
lowed up on the children at age 14.
According to a report in the February
2004 issue of The Journal of Pediatrics, the
children continued to have problems,
including neurological changes and
decreased nervous control of the heart.
In contrast, the authors of the
Seychelles study found little evidence of
lasting harm on a cohort of 66-month-old
children, according to their report in the
26 August 1998 issue of JAMA. A follow-
up study, published in the 17 May 2003
issue of The Lancet, similarly found no
lasting effects on language, memory,
motor skills, or behavioral function when
the children were 9 years old.
The different outcomes of the two stud-
ies are puzzling because the children of
both populations appeared to be exposed to
similar amounts of methylmercury. Several
explanations have been proposed, including
the possibility that genetic differences
between the populations may alter their rel-
ative predispositions to harm from mercury
exposure. The source of methylmercury is
also different in the two populations. The
Faroese are exposed primarily through the
consumption of pilot whale meat, whereas
the Seychelles population relies heavily on
ocean fish. According to Gary Myers, a pro-
fessor of neurology and pediatrics at the
University of Rochester Medical Center
and one of the principal investigators of the
Seychelles study, whale meat contains many
other contaminants (including PCBs)
besides methylmercury. “There is also evi-
dence,” he says, “that the effects of con-
comitant PCB and mercury exposure are
synergistic.”
Researchers continue to look at whether
there is a danger from methylmercury at
the levels of exposure achieved by fish con-
sumption. Another layer of uncertainty was
added with findings published in the
October 2005 issue of EHP showing that
fish consumption during pregnancy
appeared to boost infant cognition—but
only as long as mercury intake, as measured
in maternal hair, wasn’t too high.
The question of whether low levels of
mercury are harmful has also manifested
itself in a controversy over the use of vac-
cines containing thimerosal, a preservative.
Although thimerosal was removed from
many of these vaccines in 2001, children
that were immunized before that date could
have received a cumulative dose of more
than 200 µg/kg of mercury with the routine
complement of childhood vaccinations,
according to a study in the May 2001 issue
of Pediatrics. Thimerosal is nearly half ethyl-
mercury by weight. Because ethylmercury is
an organic form of mercury, there is some
suspicion that it acts like methylmercury in
the brain, although research published in
Focus | New Thinking on Neurodevelopment
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of U.S. children diagnosed with ADHD
between 1990 and 1998.  CNS Drugs,
February 2002the August 2005 issue of EHP suggests that
the two forms differ greatly in how they are
distributed through and eliminated from
the brain. Developing countries continue to
use pediatric vaccines that contain
thimerosal. In the United States, thimerosal
is still present in influenza vaccines, which
the CDC recommends be given to pregnant
women and children aged 6–23 months.
Advocacy groups, such as SafeMinds,
have suggested that the decades-long rise in
the diagnosis of autism is related to the
presence of thimerosal in vaccines. In May
2004, however, the Institute of Medicine
(IOM) issued a report, Immunization Safety
Review: Vaccines and Autism, stating that
several epidemiological studies published
since 2001 “consistently provided evidence
of no association” between thimerosal-
containing vaccines and autism. However,
the IOM’s report has been severely criti-
cized by a number of advocacy groups,
including the National Autism Association,
for relying too heavily on a specific set of
epidemiologic data while dismissing clini-
cal evidence and other epidemiologic stud-
ies that showed evidence of a link.
Despite the assurances of the IOM,
some scientists continue to explore the
mechanisms underlying the potential neu-
rotoxic effects of thimerosal. In the January
2005 issue of NeuroToxicology, S. Jill James,
a professor of pediatrics at the University
of Arkansas for Medical Sciences, and her
colleagues report that the neuronal and
glial cell toxicity of methylmercury and
ethylmercury (as dosed via thimerosal) are
both mediated by the depletion of the
antioxidant peptide glutathione. Of the
two cell types, neurons were found to be
particularly susceptible to ethylmercury-
induced glutathione depletion and cell
death, according to James, and pretreat-
ment of the cells with glutathione reduced
these effects. Other studies by James and
her colleagues, reported in the December
2004 issue of the American Journal of
Clinical Nutrition, showed that autistic chil-
dren had lower levels of glutathione com-
pared to normal controls, and may therefore
have had a significant reduction in the abil-
ity to detoxify reactive oxygen species. 
James says the abnormal profile “sug-
gests that these children may have an
increased vulnerability to pro-oxidant envi-
ronmental exposures and a lower threshold
for oxidative neurotoxicity and immuno-
toxicity.” Speaking at the XXII Internat-
ional Neurotoxicology Conference in
September 2005, she presented evidence
that multiple genetic polymorphisms
affecting glutathione pathways may interact
to produce a chronic metabolic imbalance
that could contribute to the development
and clinical symptoms of autism. Her
paper in the American Journal of Clinical
Nutrition reported that low glutathione
levels in many autistic children were
reversible with targeted nutritional inter-
vention, but the ramifications of this find-
ing are still unclear.
Manganese. As an essential nutrient,
manganese is required for normal develop-
ment; the reference dose for manganese is
0.14 mg/kg/day. Chronic occupational
exposure to high levels of this metal is
associated with manganism, a condition
reminiscent of Parkinson disease that is
characterized by tremors, rigidity, and
psychosis. The illness is seem primarily
among miners. 
Animal studies published in the August
2005 issue of Neurotoxicology by David
Dorman, director of the division of biolog-
ical sciences at the CIIT Centers for Health
Research in Research Triangle Park, North
Carolina, suggest that the fetus is protected
to a certain extent from maternally inhaled
manganese. According to Dorman, chil-
dren are exposed to manganese primarily by
ingesting it, but he knows of no link
between childhood exposure to manganese
and later Parkinson disease. 
Nevertheless, because manganese affects
the adult brain, people suspect that the
developing brain may be even more suscep-
tible to harm from this metal, and recent
research has unveiled a new cause for con-
cern: In the January 2006 issue of EHP,
child psychiatry professor Gail Wasserman
and colleagues from Columbia University
reported that Bangladeshi children who
drank well water with high concentrations
of naturally occurring manganese had
diminished intellectual function. The
researchers noted that the bioavailability of
manganese in water is higher than that of
manganese in food. They also pointed out
that about 6% of U.S. wells have a high
enough manganese content to potentially
put some children at risk for diminished
intellectual function. 
The cellular and molecular mecha-
nisms of manganese neurotoxicity are not
well understood. The dopaminergic system
in the basal ganglia, which is affected in
Parkinson disease, may be involved, but
this hypothesis is controversial. Tomás
Guilarte, a professor of molecular neuro-
toxicology at the Johns Hopkins Bloom-
berg School of Public Health, described
research on these systems in nonhuman
primates at the XXII International Neuro-
toxicology Conference. According to
Guilarte, unpublished positron-emission
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tomography studies of the basal ganglia
show that “manganese does appear to have
an effect on dopaminergic neurons.”
Guilarte found that the more manganese
the animals received, the less dopamine was
released through the actions of ampheta-
mine (which is used to induce the release of
the neurotransmitter). “This does not
mean that manganese causes Parkinson’s
disease, merely that it has an effect on those
neurons,” he says. This is the first report of
an in vivo effect on dopamine release by
manganese.
PCBs, PBDEs, and pesticides. Many
chemicals raise concerns because of their
persistence in the environment and their
tendency to bioaccumulate in animal tis-
sues. They are typically synthetic molecules
that were designed for use in everyday
products, such as electrical equipment,
computers, furniture, and pesticides. 
PCBs appear to be present in all parts of
the food chain, and humans are exposed to
these molecules primarily through the
ingestion of animal fat. The toxicity of
these chemicals was first recognized after
mass poisonings in Japan in 1968 and
Taiwan in 1979. Children born to women
who had ingested contaminated cooking oil
in Taiwan had a number of developmental
abnormalities, including psychomotor
delay and lower scores on cognitive tests,
according to a report in the 15 July 1988
issue of Science. 
Since those earlier observations, several
studies have described a connection
between prenatal exposure to PCBs and
delayed cognitive development and lower
IQ. For example, a study in the 10
November 2001 Lancet reports those
infants and young children exposed to
PCBs through breast milk scored lower on
tests of psychomotor and mental develop-
ment. The mothers were exposed to normal
background levels of PCBs in Europe. In
response to such studies, the U.S. Food and
Drug Administration set tolerance levels for
PCBs in a number of consumer products,
such as milk and manufactured dairy prod-
ucts (1.5 parts per million), poultry (3.0
parts per million), and baby food (0.2 part
per million).
PBDEs are widely used as flame retar-
dants in consumer products. The effects of
PBDEs on humans is not clear, but animal
toxicity studies described in volume 183
(2004) of Reviews of Environmental Con-
taminants and Toxicology show that PBDEs
can cause permanent learning and memory
impairments, hearing deficits, and behav-
ioral changes. There is a growing concern
about PBDEs because they appear to be
accumulating in human tissues. Andreas
Sjödin, a toxicologist at the CDC, and col-
leagues found a trend toward increasing
concentrations of PBDEs in human serum
taken from sample populations in the
southeastern United States from 1985
through 2002, and in Seattle, Washington,
from 1999 through 2002. This report
appears in the May 2004 EHP. Several
studies have also discovered PBDEs in
human breast milk. The current EPA refer-
ence dose for PBDEs is 2 mg/kg/day.
As for pesticides, it’s been suggested by
zoologist Theo Colborn of the University of
Florida that every child conceived today in
the Northern Hemisphere is exposed to
these chemicals from conception through
gestation and beyond. Some pesticides
appear to be more harmful than others, and
so the reference dose varies somewhat from
one compound to another.
The effects of pesticides on the devel-
oping brain have been investigated in
human epidemiologic studies and in labo-
ratory experiments with animals. Vincent
Garry, a professor of environmental medi-
cine at the University of Minnesota, and
his colleagues found that children born to
applicators of the fumigant phosphine
were more likely to display adverse neuro-
logical and neurobehavioral developmental
effects. The herbicide glyphosate was also
linked to neurobehavioral effects, accord-
ing to the same report, which appeared in
the June 2002 issue of EHP Supplements.
Another epidemiologic study, reported in
the March 2005 issue of NeuroToxicology,
showed that women who were exposed to
organophosphate pesticides in an agricul-
tural community in California had chil-
dren who displayed adverse neurodevelop-
mental effects, and that higher levels of
pesticide metabolites in maternal urine
were associated with abnormal reflexes in
the women’s newborn children.  
Many PCBs, PBDEs, and pesticides are
the subject of the 2001 Stockholm Con-
vention on Persistent Organic Pollutants,
which became international law in May
2004. The goal of the treaty is to “rid the
world of PCBs, dioxins and furans, and
nine highly dangerous pesticides,” accord-
ing to the United Nations Environment
Programme. Implementation of the treaty
has significant practical challenges, how-
ever, including the difficulty of eliminat-
ing one persistent pollutant without
creating another (for example, when
burning PCBs yields by-products such as
dioxins and furans).
Not Immune to Harm
Exposure to a neurotoxicant may not be the
only way to disrupt the natural growth of
the brain. Scientists are now looking at the
subtle physiological effects of immunotoxi-
cants and infectious agents on biological
events during development.
It turns out that mothers who experi-
ence an infection during pregnancy are at a
greater risk of having a child with a neuro-
developmental disorder such as autism or
schizophrenia. For example, prenatal expo-
sure to the rubella virus is associated with
neuromotor and behavioral abnormalities
in childhood and an increased risk of schiz-
ophrenia spectrum disorders in adulthood,
according to an article in the March 2001
issue of Biological Psychiatry. Rubella has
also been linked to autism: some 8–13% of
children born during the 1964 rubella pan-
demic developed the disorder, according to
a report in the March 1967 Journal of
Pediatrics. The same study also noted a con-
nection between the rubella virus and men-
tal retardation. 
Some epidemiologic studies have found
an increased risk of schizophrenia among the
children of women who were exposed to the
influenza virus during the second trimester
of pregnancy, according to a report in
the February 2002 Current Opinion in
Neurobiology. In the August 2004 Archives of
General Psychiatry, Ezra Susser, head of epi-
demiology at Columbia University’s
Mailman School of Public Health, and his
colleagues reported that the risk of the men-
tal disorder was increased sevenfold if the
schizophrenic patient’s mother had influenza
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Annual cost in billions of dollars of
methylmercury-induced toxicity (in terms
of lost productivity). EHP, May 2005during her first trimester of pregnancy. A
prospective birth cohort study in the April
2001 Schizophrenia Bulletin found that sec-
ond trimester exposure to the diphtheria
bacterium also significantly increased the
risk of schizophrenia.
How might infectious agents cause
these disorders? According to John
Gilmore, a professor of psychiatry at the
University of North Carolina at Chapel
Hill, maternal infections during pregnan-
cy can alter the development of fetal neu-
rons in the cerebral cortex of rats. The
mechanism is far from clear, but signaling
molecules in the mother’s immune system,
called cytokines, have been implicated.
Speaking at the XXII International Neuro-
toxicology Conference, Gilmore described
in vitro experiments showing that elevated
levels of certain cytokines—interleukin-
1β, interleukin-6 and tumor necrosis fac-
tor–alpha (TNF-α)—reduce the survival
of cortical neurons and decrease the com-
plexity of neuronal dendrites in the cere-
bral cortex. “I believe that the weight of
the data to date indicates [that the mater-
nal immune response] can have harmful
effects,” says Gilmore.
Inflammatory responses in the mother
may not be the only route to modifying the
fetal brain. The University of California,
Davis, Center for Children’s Environmental
Health and Disease Prevention is conduct-
ing a large study of autistic children in
California called CHARGE (Childhood
Autism Risks from Genetics and the
Environment), which suggests that the
child’s immune system may also be
involved. According to Pessah, the study
principal investigator, children with autism
appear to have a unique immune system.
“Autistic children have a significant reduc-
tion in plasma immunoglobulins and a
skewed profile of plasma cytokines com-
pared to other children,” he says. “We think
that an immune system dysfunction may be
one of the etiological cores of autism.” 
He continues, “We know that many of
the things that kids are exposed to these
days are immunotoxicants. . . . We have
evidence that ethylmercury and thimeros-
al alter the signaling properties of antigen-
presenting cells, known as dendritic cells,
at nanomolar levels.” Since each dendritic
cell can activate 250 T cells, any dysregu-
lation will be magnified, he says. “Add to
that a genetic abnormality in processing
immune information, and there could be a
problem.” 
Such problems might extend to the
central nervous system. The brains of
individuals who have a neurodevelopmen-
tal disorder also show evidence of inflam-
mation. In the January 2005 issue of the
Annals of Neurology, Carlos Pardo, an
assistant professor of neurology and
pathology at the Johns Hopkins Univ-
ersity School of Medicine, and his col-
leagues report finding high levels of
inflammatory cytokines (interleukin-6,
interleukin-8, and interferon-γ) in the
cerebrospinal fluid of autistic patients.
Glial cells, which serve as the brain’s
innate immune system, are the primary
sources of cytokines in the central nervous
system. So it may not be surprising that
Pardo’s team also discovered that glia are
activated—showing both morphological
and physiological changes—in post-
mortem brains of autistic patients.
The recognition that the immune sys-
tem is involved in neurodevelopmental
disorders is changing people’s perceptions
of these conditions. “Historically, scien-
tists have focused on the role of neurons
in all kinds of neurological diseases,”
Pardo says, “but they have generally been
ignoring the [glia].” He adds, “In autism,
it could be that the [glia] are responding
to some external insult, such as an infec-
tion, an intrauterine injury, or a neuro-
toxicant.”
According to Pardo, it’s still not clear
whether the neuroimmune responses
associated with autism contribute to the
dysfunction of the brain or whether they
are secondary reactions to some neural
abnormality. “John Gilmore’s work
[showing that cytokines can be harmful to
brain cells] is quite interesting and impor-
tant,” he says. “However, in vitro studies
may produce results that don’t reflect
what occurs under in vivo conditions.
Cytokines like TNF-α may be beneficial
for some neurobiological functions at low
concentrations, but may be extremely
neurotoxic at high concentrations.”
Lending Brain Power to Exposure
Assessment
The medical and scientific communities
recognize the colossal challenges involved
in identifying the ultimate causes of
neurodevelopmental disorders. This is
complicated by the sheer numbers of
potential exposures involved. More than
67% of the nearly 3,000 chemical com-
pounds produced or imported in amounts
exceeding 1 million pounds per year have
not been examined with even basic tests
for neurotoxicity, according to Toxic
Ignorance, a 1997 analysis by Environ-
mental Defense. 
In the past few years, several large
projects have been proposed, and funding
A 106 VOLUME 114 | NUMBER 2 | February 2006 • Environmental Health Perspectives
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The increased risk of schizophrenia in off-
spring if the mother had influenza during her
first trimester of pregnancy.  Archives of
General Psychiatry, August 2004
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by the NIH has been increased. For exam-
ple, the NIH boosted its support for
autism research from $22 million in 1997
to $100 million in 2004. In 2001, the
NIEHS and the EPA jointly announced
the creation of four new children’s envi-
ronmental health research centers (includ-
ing the one at the University of
California, Davis), which focus primarily
on neurodevelopmental disorders. More
recently, the proposed multibillion-dollar
National Children’s Study, which is
cosponsored by the Department of
Health and Human Services and the EPA,
has been designed to follow nearly
100,000 children over the course of 21
years. The investigators plan to study the
effects of environmental factors on chil-
dren’s growth and development, including
impacts on learning, behavior, and mental
health. Study investigators hope to enroll
the first participants in early 2007. 
Scientists also see the need for design-
ing better studies. In neurodevelopmental
studies, as in any other field, the quality
of a study is only as good as all of its parts.
Jean Harry, head of the NIEHS Neuro-
toxicology Group, says, “You can have a
valid assessment of behavior, but in the
absence of good exposure data, a causative
association with environmental factors
will be compromised.” 
In a bid to address the difficulties
faced by epidemiologic studies that look
for neurodevelopmental effects from in
utero chemical exposure, a working group
of 20 experts gathered in September 2005
under the auspices of the Penn State
Hershey Medical Center, coincident with
the XXII International Neurotoxicology
Conference. The goal of their day-long
session was to develop a scheme of best
practices for the design, conduct, and
interpretation of future investigations, as
well as the practical inclusion of new
technologies, such as imaging. 
At one point in the dialogue, the
group recognized that perhaps the greatest
challenge in these studies was determin-
ing how to evaluate in utero exposures to
environmental chemicals. “Quite often
the very nature of epidemiological studies
limits the ability to perform accurate
exposure assessments,” says Harry, who
was part of the expert group. “Such expo-
sures may have occurred in the distant
past, they may have been unknown, or
they may have been in conjunction with
many other compounds.” 
The group therefore recommended
that actual measurements, even if indi-
rect, are better than methods based on
subject recall. It also recommended that a
well-defined hypothesis should form the
foundation of in utero studies for assessing
neurodevelopmental outcomes. “[These
and other] conclusions will move the sci-
ence forward by describing methods that
should improve interstudy comparisons,
and they offer ways in which research
results should be reported to the scientif-
ic and medical communities,” says Judy
LaKind, an adjunct associate professor of
pediatrics at the Hershey Medical Center
and a member of the workshop steering
committee. The complete workshop
report will be published in an upcoming
issue of NeuroToxicology.
Imagining the Big Picture
The challenges of addressing neurodevel-
opmental disorders are more than scientif-
ic. The difficulties come together at a
crossroads where the communication of
knowledge, the treatment of patients, and
the regulation of potentially toxic chemi-
cals meet. Says Herbert, “Evidence-based
medicine has not yet developed standards
for assessing, or practices for treating, the
impacts of chronic, multiple low-dose
exposures.” Rather than waiting, she says,
patients and parents of patients are turning
to alternative medicine to address their
concerns.
That’s not always a good thing, espe-
cially when patients and parents may be
misinformed. Kathy Lawson, director of
the Healthy Children Project at the
Learning Disabilities Association of
America, says there is a disconnect
between scientific knowledge and the pub-
lic’s awareness of ways to reduce the inci-
dence of some disorders. “In my visits to
various organizations, I’ve discovered that
people are completely unaware that there
is a connection between environmental
toxicants and their health,” she says. “Even
pediatricians often don’t know about these
things,” she adds. 
Educating the public is only part of the
solution. Elise Miller, executive director of
the nonprofit Institute for Children’s
Environmental Health, thinks that federal
regulatory agencies do not adequately pro-
tect children’s health. “The Toxic Sub-
stances Control Act, which was passed
thirty years ago, needs a major overhaul to
ensure neurotoxicants and other chemicals
are prioritized, screened, and tested prop-
erly,” she says. “Currently, there are too
many chemicals on the market and in the
products we use every day for which there
is no toxicity data.” 
Some politicians agree with these sen-
timents. In July 2005, Senator Frank R.
Lautenberg (D–NJ) introduced the Child,
Worker, and Consumer Safe Chemicals
Act, which initially calls for chemical
manufacturers to provide health and safe-
ty information on the chemicals used in
certain consumer products, among them
baby bottles, water bottles, and food pack-
aging. If passed into law, the bill, coau-
thored by Senator James Jeffords (I–VT),
would require all commercially distributed
chemicals to meet the new safety measures
by 2020.
The human brain is often touted as
the most complex structure in the known
universe. The developmental process that
produces this remarkable entity may also
be among the most delicate in nature. As
one scientist put it, “The brain doesn’t
like to be jerked around.” That kind of
fragility makes it difficult for scientists to
untangle genetic influences from what
often may be subtle environmental
assaults. Even so, the catalogue of harmful
environmental agents will undoubtedly
continue to grow as scientists learn more
about the interactions between the devel-
oping brain and its environment. The
hope is that enough good minds will use
that catalogue to create a future with
healthier brains and more peace of mind
for parents and society alike.
Michael Szpir
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67
Percentage of high-production-volume chemicals
produced in or imported into the United States
that have not been examined for neurotoxicity.
Toxic Ignorance, 1997
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